Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12883359 | 0.83 | POLB (0.43) | POLBGAAPDE4AAGO2ALDH1A1 | |
| SCHEMBL26538070 | 0.77 | MAPT (0.41) | POLBGAAPDE4AAGO2ALDH1A1 | |
| SCHEMBL20355508 | 0.76 | POLB (0.38) | POLBGAAPDE4AAGO2ALDH1A1 | |
| SCHEMBL2722102 | 0.74 | PDE4A (0.46) | POLBGAAPDE4AAGO2ALDH1A1 | |
| SCHEMBL4915813 | 0.72 | NOS3 (0.60) | POLBGAAPDE4AAGO2ALDH1A1 | |
| SCHEMBL17700671 | 0.71 | NUDT1 (0.42) | POLBGAAPDE4AAGO2ALDH1A1 | |
| SCHEMBL12010925 | 0.68 | PDE4A (0.53) | POLBPDE4AAGO2ALDH1A1KDM4E | |
| SCHEMBL15920456 | 0.68 | PDE4A (0.39) | POLBPDE4AAGO2ALDH1A1MAPT | |
| SCHEMBL12262320 | 0.67 | TRPM8 (0.45) | POLBGAAPDE4AAGO2ALDH1A1 | |
| SCHEMBL12230238 | 0.67 | MAPT (0.45) | POLBGAAPDE4AAGO2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021462-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190152948-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021462-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | POLB 3486/4885GAA 4444/4885PDE4A 3194/4885 |
| US-20190152948-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | POLB 3486/4885GAA 4444/4885PDE4A 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.